46 related articles for article (PubMed ID: 20190808)
21. Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription.
Torosyan Y; Dobi A; Naga S; Mezhevaya K; Glasman M; Norris C; Jiang G; Mueller G; Pollard H; Srivastava M
Cancer Res; 2006 Oct; 66(19):9609-16. PubMed ID: 17018618
[TBL] [Abstract][Full Text] [Related]
22. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
Torosyan Y; Simakova O; Naga S; Mezhevaya K; Leighton X; Diaz J; Huang W; Pollard H; Srivastava M
Int J Cancer; 2009 Dec; 125(11):2528-39. PubMed ID: 19610065
[TBL] [Abstract][Full Text] [Related]
23. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
24. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons.
Nagano K; Masters JR; Akpan A; Yang A; Corless S; Wood C; Hastie C; Zvelebil M; Cramer R; Naaby-Hansen S
Oncogene; 2004 Mar; 23(9):1693-703. PubMed ID: 14647428
[TBL] [Abstract][Full Text] [Related]
25. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
26. Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANXA7 in prostate cancer cells.
Torosyan Y; Dobi A; Glasman M; Mezhevaya K; Naga S; Huang W; Paweletz C; Leighton X; Pollard HB; Srivastava M
Oncogene; 2010 Apr; 29(17):2457-66. PubMed ID: 20190808
[TBL] [Abstract][Full Text] [Related]
27. Potential role of annexin A7 in cancers.
Guo C; Liu S; Greenaway F; Sun MZ
Clin Chim Acta; 2013 Aug; 423():83-9. PubMed ID: 23639634
[TBL] [Abstract][Full Text] [Related]
28. ANXA7-GTPase as Tumor Suppressor: Mechanisms and Therapeutic Opportunities.
Leighton X; Eidelman O; Jozwik C; Pollard HB; Srivastava M
Methods Mol Biol; 2017; 1513():23-35. PubMed ID: 27807828
[TBL] [Abstract][Full Text] [Related]
29. [Progress in the study of heterogeneous nuclear ribonucleoprotein and its relation with diseases].
Chen Y; Wang YN; Zhou HH
Sheng Li Ke Xue Jin Zhan; 2008 Apr; 39(2):109-13. PubMed ID: 18664172
[TBL] [Abstract][Full Text] [Related]
30. Lung cancer and inflammation: interaction of chemokines and hnRNPs.
Tauler J; Mulshine JL
Curr Opin Pharmacol; 2009 Aug; 9(4):384-8. PubMed ID: 19570713
[TBL] [Abstract][Full Text] [Related]
31. Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression.
Barboro P; Ferrari N; Balbi C
Cancer Lett; 2014 Oct; 352(2):152-9. PubMed ID: 25016060
[TBL] [Abstract][Full Text] [Related]
32. The roles of hnRNP A2/B1 in RNA biology and disease.
Liu Y; Shi SL
Wiley Interdiscip Rev RNA; 2021 Mar; 12(2):e1612. PubMed ID: 32588964
[TBL] [Abstract][Full Text] [Related]
33. The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression.
Carpenter B; MacKay C; Alnabulsi A; MacKay M; Telfer C; Melvin WT; Murray GI
Biochim Biophys Acta; 2006 Apr; 1765(2):85-100. PubMed ID: 16378690
[TBL] [Abstract][Full Text] [Related]
34. Roles of Splicing Factors in Hormone-Related Cancer Progression.
Takeiwa T; Mitobe Y; Ikeda K; Horie-Inoue K; Inoue S
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106418
[TBL] [Abstract][Full Text] [Related]
35. ANX7 as a bio-marker in prostate and breast cancer progression.
Srivastava M; Bubendorf L; Nolan L; Glasman M; Leighton X; Miller G; Fehrle W; Raffeld M; Eidelman O; Kallioniemi OP; Srivastava S; Pollard HB
Dis Markers; 2001; 17(2):115-20. PubMed ID: 11673658
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
